Last reviewed · How we verify
Low dose Resveratrol
Low dose Resveratrol is a Small molecule drug developed by University of Florida. It is currently in Phase 1 development. Also known as: ReserveAge.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Low dose Resveratrol |
|---|---|
| Also known as | ReserveAge |
| Sponsor | University of Florida |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
- Somnolence
- Headache
- COVID-19
- Diarrhoea
- Syncope
- Alanine aminotransferase increased
- Blood pressure increased
- Haemoglobin decreased
- SARS-CoV-2 test positive
- White blood cells urine
- Nausea
- Vomiting
Key clinical trials
- Curcumin, Resveratrol, and Stinging Nettle as Treatments for GWI (NA)
- Metabolism of Bioactive Dietary Polyphenol Preparation (BDPP) (PHASE1)
- Effect of Supplement on Appetite and GLP-1 (NA)
- Effect of Food-derived Active Components on Digestive Tract Health in Adults with Irritable Bowel Syndrome (NA)
- JOTROL PK, Safety, and Food Effect Assessment (PHASE1)
- BDPP Treatment for Mild Cognitive Impairment (MCI) and Prediabetes or Type 2 Diabetes Mellitus (T2DM) (PHASE1)
- Phase I Biomarker Study of Dietary Grape-derived Low Dose Resveratrol for Colon Cancer Prevention (PHASE1)
- A Biological Study of Resveratrol's Effects on Notch-1 Signaling in Subjects With Low Grade Gastrointestinal Tumors (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Low dose Resveratrol CI brief — competitive landscape report
- Low dose Resveratrol updates RSS · CI watch RSS
- University of Florida portfolio CI
Frequently asked questions about Low dose Resveratrol
What is Low dose Resveratrol?
Who makes Low dose Resveratrol?
Is Low dose Resveratrol also known as anything else?
What development phase is Low dose Resveratrol in?
What are the side effects of Low dose Resveratrol?
Related
- Manufacturer: University of Florida — full pipeline
- Also known as: ReserveAge
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing